In China, Winning the Tender Was Never the Hard Part
China’s national intraocular-lens agreements have begun to lapse with no renewal scheme yet published, but the renewal price is the least interesting thing about this market.
China’s first national intraocular-lens (IOL) procurement agreements lapsed at the end of May 2026. Beijing’s two-year cycle runs to 28 June; Hunan’s to 30 June. As of early June, no IOL-specific renewal scheme has been published.
That absence is not a vacuum. The device-procurement renewal template already exists in worked form: the coronary-stent second-round renewal (GH-HD2026-1) opened on 20 May 2026, pricing by inquiry rather than a fresh race to the floor, under an explicit “anti-involution” principle. The method is set. It has simply not yet been applied to lenses.
Most coverage will treat the renewal as a pricing event. That is not the part that matters.
The renewal price was never what decided whether a premium lens actually sold in China. Three things did, and a Q2 2026 review of the policy against the hospital reality makes each one sharper.
China is not one market.
At least three reimbursement regimes are running in parallel. Beijing operates a hard cap with an explicit patient top-up channel. Guangzhou removed its IOL cap entirely under Guangzhou MSA [2025] No. 1 (February 2025) and now reimburses proportionally. Shanghai, Jiangsu, Zhejiang and others have moved to DRG and DIP bundling, under which the lens stops being a billable item and becomes a cost inside a fixed case payment. A proposition that is rational in one regime is commercially irrational in another; a single national plan will misallocate in at least one of them.
“Permitted” is not “executable”.
Several provinces allow an insured patient to top up for a premium lens. In many hospitals, the billing system does not carry the code to do it. The physician can describe the option; the order cannot be placed. The map that predicts volume is the map of hospitals that have enabled the channel, not the list of cities that have published the policy.
The economics sit with the hospital, not the patient.
In a bundled region, a premium trifocal, even at its reduced procurement price, turns a single cataract case into a loss against the bundle. Without a case-by-case exclusion pathway, the hospital cannot absorb it, however willing the patient. This is why premium adoption stalls in DRG regions, and it has little to do with clinician preference.
Put together, these are the reasons the genuine premium growth in Chinese cataract surgery now sits largely outside the public reimbursement system, in private chains, commercial health cover and self-pay, and why winning the next tender, on its own, will not change a manufacturer’s trajectory.
The full Q2 2026 edition of the China IOL market access intelligence pack sets this out in operational detail: a 14-market provincial reimbursement map, the hospital cataract P&L modelled by regime, the regional and product strategy matrix, and the competitive read on how the foreign and domestic leaders are now positioning. It is written for market-access, strategy and investment teams who have to act on this rather than describe it.
intelligence@ophthallogix.com · www.ophthallogix.com
This article draws on publicly available Chinese policy and procurement sources and on OphthalLogix Intelligence’s own analysis. Factual policy and procurement points are current as of June 2026; any forward-looking or commercial interpretation is an analytical judgement, not a statement of fact, and may change as policy develops. It is provided for professional information only and does not constitute investment, legal or regulatory advice.